These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 20409738)

  • 1. DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts.
    Fantur K; Hofer D; Schitter G; Steiner AJ; Pabst BM; Wrodnigg TM; Stütz AE; Paschke E
    Mol Genet Metab; 2010 Jul; 100(3):262-8. PubMed ID: 20409738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacological chaperone N-n-butyl-deoxygalactonojirimycin enhances β-galactosidase processing and activity in fibroblasts of a patient with infantile GM1-gangliosidosis.
    Mohamed FE; Al Sorkhy M; Ghattas MA; Al-Gazali L; Al-Dirbashi O; Al-Jasmi F; Ali BR
    Hum Genet; 2020 May; 139(5):657-673. PubMed ID: 32219518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis.
    Takai T; Higaki K; Aguilar-Moncayo M; Mena-Barragán T; Hirano Y; Yura K; Yu L; Ninomiya H; García-Moreno MI; Sakakibara Y; Ohno K; Nanba E; Ortiz Mellet C; García Fernández JM; Suzuki Y
    Mol Ther; 2013 Mar; 21(3):526-32. PubMed ID: 23337983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorous iminoalditols act as effective pharmacological chaperones against gene products from GLB₁ alleles causing GM1-gangliosidosis and Morquio B disease.
    Fantur KM; Wrodnigg TM; Stütz AE; Pabst BM; Paschke E
    J Inherit Metab Dis; 2012 May; 35(3):495-503. PubMed ID: 22033734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GM1 gangliosidosis and Morquio B disease: expression analysis of missense mutations affecting the catalytic site of acid beta-galactosidase.
    Hofer D; Paul K; Fantur K; Beck M; Bürger F; Caillaud C; Fumic K; Ledvinova J; Lugowska A; Michelakakis H; Radeva B; Ramaswami U; Plecko B; Paschke E
    Hum Mutat; 2009 Aug; 30(8):1214-21. PubMed ID: 19472408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to β-galactosidase mutations: Improved synthesis and biological investigations.
    Front S; Almeida S; Zoete V; Charollais-Thoenig J; Gallienne E; Marmy C; Pilloud V; Marti R; Wood T; Martin OR; Demotz S
    Bioorg Med Chem; 2018 Nov; 26(20):5462-5469. PubMed ID: 30270003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structure of human β-galactosidase: structural basis of Gm1 gangliosidosis and morquio B diseases.
    Ohto U; Usui K; Ochi T; Yuki K; Satow Y; Shimizu T
    J Biol Chem; 2012 Jan; 287(3):1801-12. PubMed ID: 22128166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis of pharmacological chaperoning for human β-galactosidase.
    Suzuki H; Ohto U; Higaki K; Mena-Barragán T; Aguilar-Moncayo M; Ortiz Mellet C; Nanba E; Garcia Fernandez JM; Suzuki Y; Shimizu T
    J Biol Chem; 2014 May; 289(21):14560-8. PubMed ID: 24737316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy.
    Rigat BA; Tropak MB; Buttner J; Crushell E; Benedict D; Callahan JW; Martin DR; Mahuran DJ
    Mol Genet Metab; 2012 Sep; 107(1-2):203-12. PubMed ID: 22784478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
    Suzuki Y
    Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase:RTB lectin fusion.
    Condori J; Acosta W; Ayala J; Katta V; Flory A; Martin R; Radin J; Cramer CL; Radin DN
    Mol Genet Metab; 2016 Feb; 117(2):199-209. PubMed ID: 26766614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
    Kasperzyk JL; El-Abbadi MM; Hauser EC; D'Azzo A; Platt FM; Seyfried TN
    J Neurochem; 2004 May; 89(3):645-53. PubMed ID: 15086521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galactonojirimycin derivatives restore mutant human beta-galactosidase activities expressed in fibroblasts from enzyme-deficient knockout mouse.
    Tominaga L; Ogawa Y; Taniguchi M; Ohno K; Matsuda J; Oshima A; Suzuki Y; Nanba E
    Brain Dev; 2001 Aug; 23(5):284-7. PubMed ID: 11504597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive behavioral and biochemical outcomes of novel murine models of GM1-gangliosidosis and Morquio syndrome type B.
    Przybilla MJ; Ou L; Tăbăran AF; Jiang X; Sidhu R; Kell PJ; Ory DS; O'Sullivan MG; Whitley CB
    Mol Genet Metab; 2019 Feb; 126(2):139-150. PubMed ID: 30528226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of C-5a-substituted derivatives of 4-epi-isofagomine: notable β-galactosidase inhibitors and activity promotors of GM1-gangliosidosis related human lysosomal β-galactosidase mutant R201C.
    Thonhofer M; Weber P; Gonzalez Santana A; Tysoe C; Fischer R; Pabst BM; Paschke E; Schalli M; Stütz AE; Tschernutter M; Windischhofer W; Withers SG
    Carbohydr Res; 2016 Jun; 429():71-80. PubMed ID: 27063389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired elastic-fiber assembly by fibroblasts from patients with either Morquio B disease or infantile GM1-gangliosidosis is linked to deficiency in the 67-kD spliced variant of beta-galactosidase.
    Hinek A; Zhang S; Smith AC; Callahan JW
    Am J Hum Genet; 2000 Jul; 67(1):23-36. PubMed ID: 10841810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candidate molecules for chemical chaperone therapy of GM1-gangliosidosis.
    Higaki K; Ninomiya H; Suzuki Y; Nanba E
    Future Med Chem; 2013 Sep; 5(13):1551-8. PubMed ID: 24024947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (5aR)-5a-C-Pentyl-4-epi-isofagomine: A powerful inhibitor of lysosomal β-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B.
    Front S; Biela-Banaś A; Burda P; Ballhausen D; Higaki K; Caciotti A; Morrone A; Charollais-Thoenig J; Gallienne E; Demotz S; Martin OR
    Eur J Med Chem; 2017 Jan; 126():160-170. PubMed ID: 27750150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotype determining alleles in GM1 gangliosidosis patients bearing novel GLB1 mutations.
    Hofer D; Paul K; Fantur K; Beck M; Roubergue A; Vellodi A; Poorthuis BJ; Michelakakis H; Plecko B; Paschke E
    Clin Genet; 2010 Sep; 78(3):236-46. PubMed ID: 20175788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis.
    Aguilar-Moncayo M; Takai T; Higaki K; Mena-Barragán T; Hirano Y; Yura K; Li L; Yu Y; Ninomiya H; García-Moreno MI; Ishii S; Sakakibara Y; Ohno K; Nanba E; Ortiz Mellet C; García Fernández JM; Suzuki Y
    Chem Commun (Camb); 2012 Jul; 48(52):6514-6. PubMed ID: 22618082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.